Alnylam Pharmaceuticals
ALNY
260 hedge funds and large institutions have $6.22B invested in Alnylam Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 98 increasing their positions, 75 reducing their positions, and 39 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 75
18% more capital invested
Capital invested by funds: $5.26B → $6.22B (+$960M)
13% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 39
1% more funds holding
Funds holding: 257 → 260 (+3)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
17% less call options, than puts
Call options by funds: $21M | Put options by funds: $25.4M
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$187M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.9M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$14.7M |
| 5 |
SPC
Slate Path Capital
New York
|
+$12.1M |
Top Sellers
ALNY Hedge Fund Activity: Q4 2015 in Review
260 of the 3,811 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2015, worth a combined $6.22B — up 18% from $5.26B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ALNY positions and 39 closed out — a net gain of 5 holders — while 98 added to existing stakes and 75 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $187M. The largest seller was Amundi Asset Management US, exiting entirely with an estimated $50.8M sold.
- 260 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2015, up from 257 in Q3 2015.
- Funds reported $6.22B of Alnylam Pharmaceuticals stock for Q4 2015, up 18% quarter-over-quarter.
- 44 funds opened new Alnylam Pharmaceuticals positions in Q4 2015 and 39 closed out, a net change of +5 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2015 was Baillie Gifford & Co, an estimated $187M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2015 was Amundi Asset Management US, an estimated $50.8M sold.
Based on aggregated 13F filings for Q4 2015.